Angiogene Inc

Angiogene Inc. is a private biotechnology company focused on the development of innovative drug-device combinations within the interventional cardiology and neurovascular fields, which aim to minimize invasive surgical procedures.
The Company is currently developing three major technology platforms for the treatment of cerebral aneurysms, restenosis and congestive heart failure.
Licensing-out:
-Radiolabelled DNA molecule (CVS, Oncology)
-Radiation detection catheter & imaging device (endovascular)
-Radioactive coated Stent (CVS, endovascular)
-Drug-eluting Stent (CVS, endovascular)

Activity:

- Licensing & Business Development
- Research & Development

Product / Technology type(s) covered:

- Devices
- Pharmaceuticals / Therapeutics

Therapeutic targets:

- Cardiovascular
- Neurology
- Oncology
- Radiology
- Stroke

Markets Covered

a. HeadQuarter: Canada

b. Continent(s) active: North America , Europe

c. Countries active:

Corporate data:

Number of Employees: 30

Turnover:

Amount:	Year:	Currency:
-	2002	US Dollar

Year founded: 1996